Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line

Medicinal Chemistry Research

Volumn 21, Issue 7, 2012, Pages 1156-1165

  Mohan, Rhea ^a   Sharma, Ajit K ^b   Gupta, Sanjay ^b   Ramaa, C S ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

2,4 Thiazolidinedione; HDAC inhibitors; Hepatocellular carcinoma cell line; Histones

Indexed keywords

1 [N (6 (2,4 DIOXOTHIAZOLIDIN 3 YL)HEXYL)] 1 AZONIA 3,5,7 TRIAZATRICYCLO DECANE BROMIDE; 1,6 DIBROMOHEXANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (6 BROMOHEXYL) 2,4 THIAZOLIDINEDIONE; 3 (6 BROMOHEXYL)THIAZOLIDINE 2,4 DIONE; [N (6 (2,4 DIOXOTHIAZOLIDIN 3 YL)HEXYL)] AMMONIUM CHLORIDE; ANTINEOPLASTIC AGENT; BENZENECARBONYL CHLORIDE; CHELATING AGENT; HISTONE DEACETYLASE INHIBITOR; SRR 1; SRR 2; THIAZOLIDINE 2,4 DIONE; UNCLASSIFIED DRUG; ZINC CHELATING AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HEPG2; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIVER CANCER; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 84861851126     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9623-3     Document Type: Article

References (21)

1. Aoki K, Aikawa K, KawakamiM(2003)Benzimidazole compounds and drugs containing the same. US PatentUS6593323B1, July 15, 2003
2. Avila MA, Berasain C, Sangro B, Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25:3866-3884
3. Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7-17
4. Dickinson J, Fowler SJ (2002) Quantification of proteins on western blots using ECL. In: Walker JM (ed) The protein protocols handbook, 2nd edn. Humana Press, Totowa, NJ, pp 429-438
5. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193
6. 1A receptor using the crystal structure of bovine rhodopsin. Internet Electron J Mol Des 5:403-415
7. Khare SP, Khade B, Gupta S (2009) Mass spectrometry-compatible silver staining of histones resolved on acid-urea-triton PAGE. Proteomics 9(9):2589-2592
8. Lai JP, Yu C, Moser CD, Adreca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR (2006) SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 130:2130-2144
9. Mai A, Silvio M, Rotili D, Cerbara H, Valente S, Pezzi R, Simeoni S, Ragno R (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25(3):261-309
10. Marin JGJ, Castano B, Martinez-Becerra P, Rosales R, Monte MJ (2008) Chemotherapy in the treatment of primary liver tumors. Cancer Therapy 6:711-728
11. Miller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46(24):5097-5116
12. Mold DE, Weingart J, Assaraf J, Lubahn DB, Kelner DN, Shaw BR, McCarthy KS Sr (1983) Silver staining of histones in triton-acidurea gels. Anal Biochem 135:44-47
13. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
14. Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51(6): 1505-1529
15. Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y (2007) Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72:69-74
16. Roberts LR, Gores GJ (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25(2): 212-225
17. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthen R, Wehrmann M, Gregor M, Lauer UM, Bitzer M (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular cancer. Cancer 109(10):2132-2141
18. Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer agents. Curr Oncol 15(5):70-76
19. Warmus JS, Dilley GJ, Meyers AI (1993) A modified procedure for the preparation of 2,5-dihydropyrrole (3-pyrroline). J Org Chem 58:270-271
20. Waterborg JH (2002) Acid-urea-triton polyacrylamide gel electrophoresis of histones. In: Walker JM (ed) The protein protocols handbook, 2nd edn. Humana Press, Totowa, NJ, pp 113-124
21. Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103: 572-576